HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Glyburide (Glibenclamide)

An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.

Also Known As:

Glibenclamide; Diabeta; Micronase; Daonil; Euglucon 5; Euglucon N; Glybenclamide; HB-419; HB-420; Maninil; Neogluconin; HB 419; HB 420; HB419; HB420; Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-

Networked: 1658 relevant articles (134 outcomes, 210 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Simard, J Marc: 26 articles (01/2016 - 04/2006)
2.	Gerzanich, Volodymyr: 19 articles (11/2015 - 04/2006)
3.	Rahmatullah, Mohammed: 11 articles (11/2015 - 01/2011)
4.	Pari, L: 10 articles (03/2005 - 11/2002)
5.	Ivanova, Svetlana: 9 articles (11/2015 - 04/2006)
6.	Koren, Gideon: 8 articles (03/2015 - 01/2003)
7.	Rahman, Shahnaz: 8 articles (01/2014 - 01/2011)
8.	Hebert, Mary F: 7 articles (12/2014 - 12/2007)
9.	Kimberly, W Taylor: 6 articles (01/2016 - 09/2012)
10.	Sheth, Kevin N: 6 articles (01/2016 - 09/2012)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2002 - "Compared with glyburide, Mix75/25 significantly improved glycemic control in older patients with type 2 diabetes mellitus, could be administered after meals without compromising glycemic control, and was well tolerated." 01/01/1984 - "Glyburide is an improved drug for the management of non-insulin-dependent diabetes mellitus (NIDDM). " 08/01/2011 - "The type 2 diabetes mellitus patients participating in this study with variant genotypes of CYP2C9 were found to respond better to treatment with glibenclamide than those with the normal genotype. " 08/01/2011 - "The aim of this study was to investigate the influence of genetic polymorphisms of CYP2C9 on the response to glibenclamide and on glibenclamide plasma levels in type 2 diabetes mellitus patients. " 03/01/1998 - "In this study nine patients with Type 2 diabetes mellitus were subjected to four treatments in random order on separate days: (A) endurance exercise after the administration of 3.5 mg glibenclamide; (B) as A but given only 1.75 mg glibenclamide; (C) as A but with placebo; (D) rest and administration of 1.75 mg glibenclamide. "
2.	Gestational Diabetes (Gestational Diabetes Mellitus) 05/01/2001 - "A recent human study has shown glyburide to minimally cross the placenta, allowing a safe new treatment for gestational diabetes. " 03/01/2008 - "To date, there has been only one randomized controlled trial investigating the use of glyburide which found it to be safe and effective in the management of gestational diabetes mellitus. " 02/01/2008 - "Glyburide is a safe and effective treatment for gestational diabetes." 01/01/2015 - "Use of glyburide to treat gestational diabetes is linked to adverse outcomes in babies, study finds." 06/01/2010 - "Initial studies regarding glyburide for treatment of gestational diabetes are promising. "
3.	Ischemia 01/01/1999 - "From this study it seems that there is a marked decrease in CBF but this did not result in impaired myocardial function after a period of ischemia, so it appears that there are no startling side effects of glibenclamide in the ischemic rat heart." 12/01/1993 - "At concentrations of 3, 10 and 30 microM of glibenclamide, a K channel blocker, a significant reduction in the incidence of reperfusion-induced VF and VT was observed, and an attenuation in the maldistribution of myocardial ion contents induced by ischemia/reperfusion was found. " 12/01/2005 - "In Study 2, recovery of function in intermittent cross-clamp fibrillation hearts (62+/-3%) was significantly (p<0.05) higher than intermittent cross-clamp fibrillation hearts treated with glibenclamide (33+/-2%) and ischemia hearts (30+/-5%). " 01/01/2015 - "Some groups received glibenclamide (KATP channel inhibitor; 5mg/kg) before ischemia (45min) and reperfusion (24h). " 12/01/2011 - "Cardiac conduction time was prolonged by low-flow ischemia in isolated, perfused mouse hearts, which was prevented by glibenclamide. "
4.	Body Weight (Weight, Body) 10/01/2010 - "The efficacy of the root extract was found to be equivalent when compared to the standard hypoglycemic drug glibenclamide (1.25 mg/kg body weight/day, orally) in diabetic rats." 09/01/2014 - "RME and glibenclamide treated rats were maintained the body weight during the study period while as the body weight of diabetic rats had gone down. " 01/01/2013 - "The extract and glibenclamide not only prevented a further body weight loss but also maintained the body weight during the study period. " 12/01/2015 - "Group C and D received 1.0mL 500mg/kg body weight free and bound polyphenol extracts respectively while group E received 1.0mL 0.6mg/kg of glibenclamide. " 12/01/2014 - "speciosus (CSREt) in doses of 200, 400, and 600 mg/kg body weight, and 600 µg/kg body weight of the standard drug glibenclamide for 4 weeks. "
5.	Stroke (Strokes) 01/01/2016 - "Blockade of this channel by the small molecule glyburide results in improved survival and neurological outcome in multiple preclinical models of ischemic stroke. " 04/01/2014 - "The findings reviewed here provide a strong foundation for a translational research program to study glibenclamide in patients with ischemic stroke." 01/01/2016 - "A robust, compelling body of evidence suggests that an intravenous formulation of glyburide, RP-1127, can prevent swelling and improve outcome in patients with stroke. " 01/01/2016 - "Human Data Supporting Glyburide in Ischemic Stroke." 01/01/2015 - "Glibenclamide for the treatment of ischemic and hemorrhagic stroke."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Metformin (Glucophage)
4.	Blood Glucose (Blood Sugar)
5.	Adenosine Triphosphate (ATP)
6.	Glyburide (Glibenclamide)
7.	Glipizide (Glucotrol)
8.	pioglitazone (Actos)
9.	rosiglitazone (Avandia)
10.	glimepiride (Amarel)

Related Therapies and Procedures

1.	Oral Administration
2.	Chinese Traditional Medicine (Traditional Chinese Medicine)
3.	Injections
4.	Decompressive Craniectomy
5.	Therapeutics